Peptide and peptide analog protease inhibitors

Details Peptide and peptide analog protease inhibitors Peptide and peptide analog protease inhibitors

1995-01-06

1998-09-08

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

562575, A61K 3805

Patent

active

058045600

ABSTRACT:
Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m--(D).sub.m--R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide or aldehyde.

REFERENCES:
patent: 4044126 (1977-08-01), Cook et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4472305 (1984-09-01), Hansen et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4701407 (1987-10-01), Appel
patent: 4840935 (1989-06-01), Wagnon et al.
patent: 5015570 (1991-05-01), Scangos et al.
patent: 5034376 (1991-07-01), Hoover
patent: 5039511 (1991-08-01), Quay et al.
patent: 5039642 (1991-08-01), Chrobaczek et al.
patent: 5081284 (1992-01-01), Higuchi et al.
patent: 5200339 (1993-04-01), Abraham
patent: 5213962 (1993-05-01), Van Nostrand et al.
patent: 5218100 (1993-06-01), Muller-Hill et al.
patent: 5221665 (1993-06-01), Skiles
patent: 5223633 (1993-06-01), Hoppe et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5270165 (1993-12-01), Van Nostrand et al.
patent: 5284828 (1994-02-01), Hemmi et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5427931 (1995-06-01), Van Nostrand et al.
patent: 5430022 (1995-07-01), Hemmi et al.
patent: 5470833 (1995-11-01), Ishikawa et al.
patent: 5496928 (1996-03-01), Ishikawa et al.
patent: 5538845 (1996-07-01), Knops et al.
patent: 5547841 (1996-08-01), Marrotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert et al.
patent: 5612486 (1997-03-01), McConlogue et al.
McKhann, et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology, 34:939-944 (1984).
Mjalli, et al., "Activated Ketones as Potent Reversible Inhibitors of Interleukin-1.beta. Converting Enzyme," Bioorg. & Med. Chem. Lett., 4(16):1965-1968.
Mullan, et al., "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of .beta.-amyloid," Nature Genetics, 1:345-347 (1992).
Murrell, et al., "A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease," Science, 254:97-99 (1991).
O'Donnell, et al., "Synthesis of .beta.,.gamma.-Unsaturated Amino Acid Derivatives by Alkyne Carbometalation-Palladium Catalyzed Coupling with 2-Aza-.pi.-Allyl Palladium Complexes," Tetrahedron Letters, 35(50):9383-9386 (1994).
Ocain and Rich, ".alpha.-keto amide inhibitors of aminopeptidases," J. Med. Chem., 35:451-456 (1992).
Oleksyszyn and Powers, "Irreversible Inhibition of Serine Proteases by Peptidyl Derivatives of .alpha.-Aminoalkylphosphonate Diphenyl Esters," Biochem. and Biophys. Res. Comm., 161(1):143-149 (1989).
Oleksyszyn and Powers, "Irreversible Inhibition of Serine Proteases by Peptide Derivatives of (.alpha.-Aminoalkyl)phosphonate Diphenyl Esters," Biochemistry, 30:485-493 (1991).
Orlowski, et al., "Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids," Biochemistry, 32(6):1563-1572 (1993).
Palmert, et al., "Soluble derivatives of the .beta. amyloid protein precursor in cerebrospinal fluid: Alterations in normal aging and in Alzheimer's disease," Neurology, 40:1028-1034 (1990).
Patel, et al., "Activated Ketone Based Inhibitors of Human Renin," J. Med. Chem., 36(17):2431-2447 (1993).
Patel, et al., "Peptidic trifluoromethyl alcohols and ketones: A general synthesis and application as renin inhibitors," Tetrahedron Letters, 29(37):4665-4668 (1988).
Pearson and Choi, "Expression of the human .beta.-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice," Proc. Natl. Acad. Sci. USA, 90:10578-10582 (1993).
Siman et al., Proteolytic processing of .beta.-Amyloid precursor by calpain I, The Journal of Neuroscience 10(7):2400-2411 (1990).
Almkvist et al., Cerebrospinal fluid levels of .alpha.-secretase-cleave soluble amyloid precursor protein mirror cognition in a swedish family with Alzheimer disease and a Gene mutation, Arch. Neurol. 54:641-644 (1997).
Angelastro, et al., "Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones," J. Med. Chem., 37:4538-4554 (1994).
Arner, et al., "1-Chloro-2,4-dinitrobenzene Is an Irreversible Inhibitor of Human Thioredoxin Reductase," J. Biol. Chem., 270(8):3479-3482 (1995). Human Renin Inhibitory Activity," J. Med. Chem., 33:2335-2342 (1990).
Cooper, et al., "X-ray Studies of Aspartic Proteinase-Statine Inhibitor Complexes," Biochemistry, 28:8596-8603 (1989).
Cooper, et al., "X-ray Crystallographic Analysis of Inhibition of Endothiapepsin by Cyclohexyl Renin Inhibitors," Biochemistry, 31:8142-8150 (1992).
De Strooper, et al., "Basolateral Secretion of Amyloid Precursor Protein in Madin-Darby Canine Kidney Cells is Disturbed by Alterations of Intracellular pH and by Introducing a Mutation Associated with Familial Alzheimer's Disease," J. Biol. Chem., 270(8):4058-4065 (1995).
Dolle, et al., "Aspartyl .alpha.-((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1.beta. Converting Enzyme Inhibitors. Significance of the P.sub.1 and P.sub.3 Amido Nitrogens for Enzyme-Peptide Inhibitor Binding," J. Med. Chem., 37(23):3863-3866 (1994).
Harris, et al., "Characterization of a Continuous Fluorogenic Assay for Calpain L. Kinetic Evaluation of Peptide Aldehydes, Halomethyl Ketones and (Acyloxy)Methyl Ketones as Inhibitors of the Enzyme," Bioorg. & Med. Chem. Lett., 5(4):393-398 (1995).
Imperiali and Abeles, "Inhibition of Serine Proteases by Peptidyl Fluoromethyl Ketones," Biochemistry, 25:3760-3767 (1985).
Krishnamurti, et al., "Preparation of Trifluoromethyl and Other Perfluoroalkyl Compounds with (Perfluoralkyl)trimethylsilanes," J. Org. Chem., 56:984-989 (1991).
Lai, et al., "Characterization of Sorting Signals in the .beta.-Amyloid Precursor Protein Cytoplasmic Domain," J. Biol. Chem., 270(8):3565-3573 (1995).
Linderman, et al., "Unique Inhibition of a Serine Esterase," Tetrahedron Letters, 34(20):3227-3230 (1993).
Powers, et al., "Mechanism-Based Isocoumarin Inhibitors for Serine Proteases: Use of Active Site Structure and Substrate Specificity in Inhibitor Design," J. Cell Biochem., 39(1)pp. 33-46 (1989).
Rao, et al., "Specificity in the Binding of Inhibitors to the Active Site of Human/Primate Aspartic Proteinases: Analysis of P.sub.2 -P.sub.1 -P.sub.1 '-P.sub.2 ' Variations," J. Med. Chem., 36:2614-2620 (1993).
Revesz, et al., "Synthesis of P1 Aspartate-Based Peptide Acyloxymethyl and Fluoromethyl Ketones as Inhibitors of Interleukin-1.beta.-Converting Enzyme," Tetrahedron Letters, 35(52):9693-9696 (1994). Human Renin Inhibitory Activity," J. Med. Chem., 33:2326-2334 (1990).
Rosenberg, et al., "Studies Directed toward the Design of Orally Active Renin Inhibitors," J. Med. Chem., 36:449-459 (1993).
Skiles, et al., "Inhibition of Human Leukocyte Elastase (HLE) by N-Substituted Peptidyl Trifluoromethyl Ketones," J. Med. Chem., 35(4):641-662 (1992).
Veale, et al., "Nonpeptidic Inhibitors of Human Leukocyte Elastase. 5. Design, Synthesis, and X-ray Crystallography of a Series of Orally Active 5-Aminopyrimidin-6-one-Containing Trifluoromethyl Ketones," J. Med. Chem., 38:98-108 (1995).
Martichonock et al., Azarine analogs

Affiliated with

Also associated with

Rating

Peptide and peptide analog protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide and peptide analog protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide and peptide analog protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1282251